
The study performed a double-blind, randomized, placebo-controlled, phase 2 trial to evaluate the safety and efficacy of vidofludimus calcium in patients hospitalized for coronavirus disease 2019 (COVID-19) in Europe and the USA. These findings support vidofludimus calcium being safe and well tolerated in patients with COVID-19.
Like
Save
Share